KalVista

KalVista Pharmaceuticals develops oral therapies for rare diseases. Their FDA-approved EKTERLY treats hereditary angioedema (HAE) in adults and kids.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2015
Stage of Initial Investment
Series B
Initial Investment Year
2015
Kalvista Hover Image